Renovaro Biosciences Appoints Two Industry Veterans to Board

Renovaro Biosciences, a Los Angeles-based biotechnology firm, witnessed a rise in its shares on Tuesday following the appointment of two finance industry veterans to its board. The stock surged by 15% to $5.01 during afternoon trading, reflecting a over a quadruple increase in its value over the course of this year.

A Valuable Addition to the Board

Renovaro announced that Leni Boeren and Ruud Hendriks would be joining the board as independent directors in preparation for the proposed combination with artificial intelligence company GEDi Cube. Boeren brings with her an extensive 40-year career in the financial sector, having held positions at Paribas, Rabobank, Amsterdam Exchanges, and Euronext, in addition to serving as chief executive and chair of Robeco Groep. On the other hand, Hendriks boasts a career spanning 35 years, having worked at Goldman Sachs Asset Management and Robeco, as well as providing advisory services to private-equity firm KKR.

Expertise for Advancing Towards Commercialization

Renovaro Chairman Rene Sindlev expressed his enthusiasm for the new additions to the board, stating that their substantial experience in the capital markets and asset management will provide invaluable financial and business expertise as the company progresses towards commercialization.